BioGlyco supplement products (including BioGlyco Flow, BioGlyco Capsules, and BioGlyco Blood) are not affiliated with CD BioGlyco.
CD BioGlyco does not manufacture, distribute, or provide after-sales support for these consumer products. For any product-related questions, please contact the original seller directly.
This highly specialized system comprises cell-penetrating peptide TA and polyethylene glycol co-modified doxorubicin liposomes. The structural matrix incorporates hydrophilic doxorubicin hydrochloride within the central aqueous core of a high-purity phospholipid bilayer shell via an ammonium sulfate gradient, while the external boundary is co-functionalized with synthetic cell-penetrating peptide TA sequences and polyethylene glycol (PEG) chains covalently linked to lipid anchors. This dual surface modification alters the surface charge topography, membrane elasticity, and introduces a dense hydrophilic shield. The surrounding lipid shell isolates the active core while presenting the cell-penetrating peptide array for advanced surface-binding evaluations.
Source
Custom synthesis
Functional Group
Cell-penetrating peptide TA; Doxorubicin
Form
Solid or powder
Purity
≥95%
Impurities
No visible impurities to the naked eye.
Identity
HPLC/MS/NMR
Publications
Publications (0)
×
Publications
Thank you for choosing our products for your research. By sharing your publications or experimental feedback, you provide invaluable insights that help fellow scientists accelerate their discoveries. Your contribution also drives our commitment to continuous product optimization.
As a token of our appreciation, verified submissions will receive an exclusive discount code for your next order.
*Submitted research data and images may be featured on our product pages. We strictly protect your personal privacy; no sensitive contact information will ever be disclosed.
CD BioGlyco is a leading biotechnology company specializing in glycobiology. We deliver high-quality products and services to support cutting-edge research worldwide.